Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Date Posted: 
2019-06-03
Dr. Chi

The TITAN clinical trial has demonstrated that the addition of apalutamide to androgen-deprivation therapy significantly improved radiographic progression-free survival and overall survival in patients with metastatic castration-sensitive prostate cancer. These results were presented by Dr. Kim Chi at ASCO on May 31, and were written up on ASCO Daily News on June 1.  Dr. Chi is first author on the study which was published in the New England Journal of Medicine on May 31.

 

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Conference Flyer Page 1

Breast & Prostate Cancer half-day virtual conference: Saturday, September 18th, 2021

The What you Need to Know for Your Patients Post Breast & Prostate Cancer Conference, taking place online on Saturday, September 18th, 2021 from 8:00am – 1:30pm, is an accredited virtual half-day conference focusing on screening, treatment, side-effect management & emerging new therapies for breast & prostate cancer patients. Click here for more information and to register. 

Dr. Peter Black, team captain

Terry Fox Run fundraiser: September 19th, 2021

The 41st Annual Terry Fox Run is taking place on Sunday September 19, 2021. If you are able, please consider donating to our team (tax receipts issued), raising funds for the Terry Fox Foundation's ground-breaking cancer research. 

Employment

Work at the Vancouver Prostate Centre

Wednesday, September 8, 2021

Recent publication proposes a potential new therapeutic approach to treatment-resistant prostate cancer

Tuesday, August 3, 2021

Dr. Cherkasov receives 2021 Faculty of Medicine Distinguished Achievement Award

Dr. Cherkasov